FIVE3 GENOMICS LLC has a total of 115 patent applications. It increased the IP activity by 12.0%. Its first patent ever was published in 2012. It filed its patents most often in Australia, Republic of Korea and United States. Its main competitors in its focus markets computer technology, biotechnology and audio-visual technology are NELSON CHARLES F, GENEPEEKS INC and SMARTGENE GMBH.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 19 | |
#2 | Republic of Korea | 18 | |
#3 | United States | 17 | |
#4 | China | 13 | |
#5 | EPO (European Patent Office) | 11 | |
#6 | Japan | 10 | |
#7 | Israel | 9 | |
#8 | WIPO (World Intellectual Property Organization) | 9 | |
#9 | Canada | 8 | |
#10 | India | 1 |
# | Industry | |
---|---|---|
#1 | Computer technology | |
#2 | Biotechnology | |
#3 | Audio-visual technology | |
#4 | Digital networks |
# | Name | Total Patents |
---|---|---|
#1 | Sanborn John Zachary | 71 |
#2 | Vaske Charles Joseph | 61 |
#3 | Benz Stephen Charles | 60 |
#4 | Rabizadeh Shahrooz | 15 |
#5 | Stephen Charles Benz | 14 |
#6 | Benz Stephen | 14 |
#7 | Szeto Christopher | 13 |
#8 | Soon-Shiong Patrick | 12 |
#9 | Hensley Nicole | 12 |
#10 | Sedgewick Andrew J | 11 |
Publication | Filing date | Title |
---|---|---|
AU2015261708A1 | Distributed system providing dynamic indexing and visualization of genomic data | |
KR20180094150A | Systems and methods for rna analysis in functional confirmation of cancer mutations | |
US2015134662A1 | Grouping and transferring omic sequence data for sequence analysis | |
AU2014324729A1 | Systems, methods, and compositions for viral-associated tumors | |
CN105556523A | PARADIGM drug response networks | |
WO2014058987A1 | Systems and methods for tumor clonality analysis | |
EP3471103A1 | Systems and methods for learning and identification of regulatory interactions in biological pathways | |
EP3534368A1 | Distributed method providing dynamic indexing and visualization of genomic data | |
AU2012347522A1 | MDM2-containing double minute chromosomes and methods therefore |